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Prions are not only unique in the way they replicate. Also the sequence of
events triggered by peripheral prion infection, generically termed ‘peripheral
pathogenesis’, sets prions aside from all other known pathogens. Whereas most
bacteria, parasites, and viruses trigger innate and adaptive immune responses,
the mammalian immune system appears to be remarkably oblivious to prions.
Transmissible spongiform encephalopathies (TSEs) do not go along with
inflammatory infiltrates, and antibodies to the prion protein are not typically
raised during the course of the disease. On the other hand, there is conspicuous
involvement of lymphoid organs, which accumulate sizeable concentrations of
the infectious agent early during disease. Moreover, various states of immune
deficiency can abolish peripheral pathogenesis and prevent ‘take’ of infection
when prions are administered to peripheral sites. Here, we critically re-visit the
current evidence for an involvement of the immune system in prion diseases,
and will attempt to trace the elaborate mechanisms by which prions, upon entry
into the body from peripheral sites, reach the brain.
Biology of prion infection
The fastest and most efficient method for inducing spongiform encephal-
opathy in the laboratory is intracerebral inoculation of brain homogenate.
Inoculation of 106 infectious units (defined as the amount of infectivity that
will induce TSE with 50% likelihood in a given host) will yield disease in
~6 months; a remarkably strict inverse relationship can be observed
between the logarithm of the inoculated dose and the incubation time1.
However, the above situation does not correspond to what typically
happens in the field. There, acquisition of prion infectivity through any of
several peripheral routes is the rule. However, prion diseases can also be
initiated by feeding2–4, by intravenous and intraperitoneal injection5 as well
as from the eye by conjunctival instillation6, corneal grafts7 and intra-ocular
injection8.
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While only less than 1% of all reported cases of Creutzfeldt-Jakob
disease (CJD) can be traced to a defined infectious source, the bovine
spongiform encephalopathy (BSE) epizootic has highlighted oral exposure
as a tremendously efficient vector for bovine prion diseases. BSE is most
likely transmissible to humans, and strong circumstantial evidence suggests
that BSE is the cause of variant Creutzfeldt-Jakob disease (vCJD).
Several aspects of CJD epidemiology continue to be enigmatic. For
example, CJD incidence in Switzerland rose 2-fold in 2001, and
increased further in 20029. A screen for recognized or hypothetical risk
factors for CJD has, to date, not exposed any causal factors. Several
scenarios may account for the increase in incidence, including improved
reporting, iatrogenic transmission, and transmission of a prion zoonosis.
Prion diseases typically exhibit a very long latency period between the
time of infection and the clinical manifestation. From the viewpoint of
interventional approaches, this peculiarity may be exploitable, since it
opens a possible window of intervention after infection has occurred,
but before brain damage is being initiated. Prions spend much of this
latency time executing neuro-invasion, which is the process of reaching
the central nervous system (CNS) after entering the body from
peripheral sites10,11. During this process, little or no damage occurs to
brain, and one might hope that its interruption may prevent neuro-
degeneration.
Immune cells and the peripheral entry sites of prions
For a long time, two routes of infection have suggested that immune
cells might be of importance for peripheral pathogenesis – oral challenge
and administration by scarification. Upon oral challenge, an early rise in
prion infectivity can be observed in the distal ileum of infected
organisms: this applies to several species but was most extensively
investigated in sheep12,13. There, Peyer’s patches acquire strong
immunopositivity for the prion protein. Immunohistochemical stains
with antibodies to the prion protein typically reveal a robust signal in
primary B-cell follicles and germinal centres, which roughly co-localizes
with the complement receptor, CD35, in a wide variety of secondary
lymphoid organs including appendix and tonsils14. Although
conventional light microscopy does not allow differentiating between
PrPC and PrPSc, Western blot analysis has left no doubt that Peyer’s
patches do accumulate the disease-associated form of the prion protein.
The latter is true also in the mouse model of scrapie, which is being
used as a convenient experimental paradigm by many laboratories
including ours. Administration of mouse-adapted scrapie prions (Rocky
Mountain Laboratory or RML strain, originally derived from the
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Chandler sheep scrapie isolate) induces a surge in intestinal prion
infectivity as early as a few days after inoculation15.
All of the above evidence conjures the suspicion that Peyer’s patches
may represent a portal of entry for orally administered prions, on their
journey from the luminal aspect of the gastro-enteric tube to the CNS.
However, the question as to whether the same applies for BSE-affected
cattle has been answered less unambiguously.
In a monumental study of BSE pathogenesis in cattle, cows of various
ages were fed with 100 g, 10 g, 1 g, or 100 mg of brain homogenate
derived from BSE-sick cows16. A large variety of tissues was taken at
various points in time, homogenized, and transmitted intracerebrally to
indicator organisms in order to assess their prion content. This study
uncovered a transient surge in infectivity in the distal ileum of cows at
approximately 6 months’ post-infection. Infectivity then subsides, but it
appears to return to the terminal ileum at the end stages of disease,
maybe by a type of retrograde transport17. Although this was not
formally confirmed, it appears likely that Peyer’s patches are the sites of
prion accumulation in the gastrointestinal tract of cattle challenged
orally with prions.
Prions and the gut
Membranous epithelial cells (M-cells) are key sites of antigen sampling
for the mucosal-associated lymphoid system (MALT) and have been
recognized as major ports of entry for enteric pathogens in the gut via
transepithelial transport18. Interestingly, maturation of M-cells is
dependent on signals transmitted by intra-epithelial B-cells. The group
of Kraehenbuhl (Lausanne) has developed efficient in vitro systems, in
which epithelial cells can be instructed to undergo differentiation to cells
that resemble M-cells by morphological and functional/physiological
criteria. Therefore, we investigated whether M-cells are a plausible site
of prion entry in a co-culture model19. Colon carcinoma cells were
cultured on the upper face of filters until confluency. Next, B-
lymphoblastoid cells were added onto the lower side of the filters.
Lymphoid cells migrated through the pores of the filter and settled
within the epithelial monolayer (Plate XIII), inducing differentiation of
M-cells. Scrapie prions were administered to the apical compartment of
co-cultures that combined integrity and active transport of beads.
Infectivity was determined within the basolateral compartment by
bioassay with tga20 mice, which overexpress a Prnp transgene and
develop scrapie rapidly after infection20. Upon challenge with scrapie
prions, we consistently recovered prions in the basolateral compartment
of co-cultures containing M-cells, suggesting transepithelial prion
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transport (Plate XIII). In contrast, there was hardly any prion transport
in Caco-2 cultures without M-cells21.
These findings indicate that M-cell differentiation is necessary and
sufficient for active transepithelial prion transport in vitro. M-cell-
dependent uptake of foreign antigens or particles is known to be
followed by rapid transcytosis directly to the intra-epithelial pocket,
where key players of the immune system (e.g. macrophages, dendritic
cells and lymphocytes18) are located. Therefore, prions may exploit M-
cell-dependent transcytosis to gain access to the immune system.
While these findings suggest that M-cells are a plausible candidate for
the mucosal portal of prion infection, it still remains to be established
whether the pathway delineated above does indeed represent the first
portal of entry of orally administered prions into the body.
Prions and the skin
Scarification of the most superficial layers of the skin, and subsequent
administration of prions, has been known for a long time to be a highly
efficacious method of inducing prion disease22,23. Dendritic cells (professional
antigen-presenting cells abundant in the skin) may become loaded with the
infectious agent by this method; in fact, recent work has implicated dendritic
cells as potential vectors of prions in oral24 and haematogenous spread25 of
the agent. It is equally possible, however, that scarification induces direct
neural entry of prions into skin nerve terminals. The latter hypothesis has not
yet been studied in much detail, but it would help explain the remarkable
speed with which CNS pathogenesis follows inoculation by this route:
dermal inoculation of scarified mice yields typical latency periods of the
disease that are similar to those obtained by intracerebral inoculation. The
possibility of direct neural spread of the agent has also been suggested by a
series of elegant experiments in the laboratories of Oldstone and Chesebro:
transgenic mice that lack the endogenous prion gene but express a Prnp
transgene exclusively in nervous tissue (under transcriptional control of the
neuron-specific enolase regulatory elements) can be efficiently infected by the
oral route despite lack of prion protein expression in lymphoid organs26. Of
course, these experiments do not exclude the possibility that dendritic or
other mobile cells may participate to neuro-invasion even if they do not
express endogenous PrPC.
Prions and lymphocytes
The normal prion protein is consistently expressed, albeit at moderate
levels, in circulating lymphocytes27. Innate or acquired deficiency of
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lymphocytes impairs peripheral prion pathogenesis, whereas no aspects
of pathogenesis are affected by the presence or absence of lymphocytes
upon direct transmission of prions to the CNS28,29. Klein described the
requirement for B-cells10,30: this was surprising since there had been no
suggestions that humoral immunity would be involved in prion diseases.
In the same study, it was shown that T-cell deficiency brought about by
ablation of the T-cell receptor α-chain did not affect prion pathogenesis.
On the other hand, lymphocytes alone could not account for the entirety
of prion pathogenesis, and an additional sessile compartment had to be
involved, since adoptive transfer of Prnp+/+ bone marrow to Prnpo/o
recipient mice did not suffice to restore infectibility of Prnp-expressing
brain grafts, indicating that neuro-invasion was still defective31.
It then emerged that peripheral prion pathogenesis required the
physical presence of B-cells, yet intraperitoneal infection occurred
efficiently even in B-cell deficient hosts that had been transferred with B-
cells from Prnp knockout mice32. Therefore, the presence of B-cells – but
not expression of the cellular prion protein by these cells – is
indispensable for pathogenesis upon intraperitoneal infection in the
mouse scrapie model33.
These results have been reproduced and confirmed several times over
the years by many laboratories in various experimental paradigms: the
requirement for B-cells in particular appears to be very stringent in most
instances investigated.
Prion strains and lymphotropism
An interesting discrepancy that remains to be addressed concerns the
actual nature of the cells that replicate and accumulate prions in
lymphoid organs. With prions of the RML strain, four series of
rigorously controlled experiments over 5 years34–37 unambiguously
reproduced the original observation that transfer of wild-type bone
marrow cells (or fetal liver cells) to Prnp-deficient mice restored
accumulation and replication of prions in spleen31. By contrast, Brown
and colleagues reported a diametrically opposite outcome of similar
experiments when mice were inoculated with prions of the ME7 strain38.
Since trivial experimental artefacts appear unlikely, this discrepancy may
identify yet another significant difference in the cellular tropism of
different prion strains.
It is important to note that the Blättler results do not necessarily
indicate that lymphocytes are the primary splenic repository of prions.
Instead, bone marrow transplantation may: (i) transfer an ill-defined
population with the capability to replenish splenic stroma and to
replicate prions; or, less probably, (ii) donor-derived PrPC-expressing
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haematopoietic cells may confer prion replication capability to recipient
stroma by virtue of ‘GPI painting’, i.e. the post-translational cell-to-cell
transfer of glycophosphoinositol-linked extracellular membrane
proteins39. Stromal splenic follicular dendritic cells (FDCs) have been
described by some authors to possibly derive from haematopoietic
precursors, particularly when donors and recipients were young40,41.
Conversely, instances have been described in which transfer of GPI-
linked proteins occurs in vivo with surprisingly high efficiency42. GPI
painting has been described specifically for the cellular prion protein43.
While it has been known for a long time that specific strains of prions
may preferentially affect specific subsets of neurons, the Blättler/Brown
paradox may uncover an analogous phenomenon in peripheral prion
pathogenesis. The latter question may be important, since the molecular
and cellular basis of peripheral tropism of prion strains is likely to be
directly linked to the potential danger of BSE in sheep44–46, as well the
potential presence of vCJD prions in human blood47.
Prion reservoirs in the periphery of the body
Prion infectivity rises very rapidly (in a matter of days) in the spleen of
intraperitoneally infected mice. Although B lymphocytes are crucial for
neuro-invasion, a series of prion titrations in Prnp-expressing and Prnp-
ablated mice, as well as reciprocal bone marrow chimeras thereof, has
ruled out that the bulk of infectivity might be contained in lymphocytes.
Instead, most splenic prion infectivity may reside in a ‘stromal’ fraction.
Therefore, lymphocytes may be important for trafficking prions within
lymphoid organs, but they do not appear to represent the major hideout
for the infectious agent. Follicular dendritic cells are a prime candidate
prion reservoir, since they express large amounts of cellular prion
protein and PrP accumulations tend to co-localize with FDCs in light
and electron microscopical analyses of prion-infected spleens. Elegant
immuno-electron microscopic studies have shown that prion
immunoreactivity is situated in the immediate neighbourhood of
iccosomes on the surface of FDCs48.
A definitive assessment of the contribution of FDCs to prion patho-
genesis continues to be problematic since the histogenesis and the
molecular characteristics of these cells are ill-defined. There is a dearth
of molecular markers for FDCs. FDCs express S-100 proteins, as well as
the complement receptors 2 (CD35) and 4 (identical to the marker FDC-
M2). All of these markers, however, are also expressed by additional cell
types, even within lymphoid organs49. The FDC-M1 marker recognized
by hybridoma clone 4C11 appears to be more specific, but it stains also
tingible body macrophages which are most likely of haematopoietic origin.
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Gene-deletion experiments in mice have shown that signalling by TNF
and lymphotoxins is required for FDC development50–52. Membrane-
bound lymphotoxin-α/β (LT-α/β) heterotrimers signal through the LT-β
receptor (LT-βR)53 which activates a pathway required for the
development and maintenance of secondary lymphoid organs54,55.
Membrane LT-α/β heterotrimers are mainly expressed by activated
lymphocytes56,57. Maintenance of pre-existing FDCs in a differentiated
state requires continuous interaction with B-lymphocytes expressing
surface LT-α/β58. Inhibition of the LT-α/β pathway in mice by treatment
with LT-βR–immunoglobulin fusion protein (LT-βR–Ig)59 leads to the
disappearance of mature, functional FDCs (defined as cells that express
markers such as FDC-M1, FDC-M2 or CD35) within 1 day, both in
spleen and in lymph nodes55,60. Prolonged administration of the LT-
βR–Ig protein leads to disruption of B-cell follicles.
Montrasio and colleagues studied the effect of selective ablation of
functional FDCs on the pathogenesis of scrapie in mice. FDC depletion
was maintained by weekly administration of the LT-βR–Ig fusion protein
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Fig. 1 Depletion of follicular dendritic cells by pharmacological inhibition of lymphotoxin
signalling. Time course of FDC depletion in spleen of LT-βR–Ig treated mice. Frozen sections
of treated (left) and control mice (right) immunostained with FDC-specific antibody FDC-M1
at different times points after injection of LT-βR–Ig (original magnifications: upper row
8x25; lower row 8x63). Germinal centre FDC networks were already depleted 1 week after
treatment60,66. Some FDC-M1 positive cells, which may represent residual FDCs or tingible
body macrophages, were still detectable in the spleens of treated mice.
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for 8 weeks. Histological examination of spleen sections revealed that FDC
networks had disappeared 1 week after treatment (Fig. 1), as expected.
In mice, following peripheral inoculation, infectivity in the spleen rises
within days and reaches a plateau after a few weeks61–63. Even after
intracerebral inoculation, spleens of C57BL/6 animals already contain
infectivity 4 days’ post-infection (p.i.)61. However, Western blot analysis
(Plate XIV) revealed that 8 weeks after inoculation spleens of control
mice showed strong bands of protease-resistant PrP, whereas mice
injected weekly with LT-βR–Ig, starting either 1 week before or 1 week
after inoculation, showed no detectable signal (less than 1/50th of the
controls).
In spleens of mice treated with LT-βR–Ig 1 week before intraperitoneal
inoculation, no infectivity could be detected after 3 or 8 weeks (< 1.0
logID50 units/ml 10% homogenate). In mice treated with LT-βR–Ig 1
week after inoculation the titres were about 2.2 and 4.1 logID50 units/ml
10% homogenate at 3 weeks and at borderline detectability at 8 weeks
after infection, suggesting that some prion accumulation took place in
the first weeks after inoculation but was reversed under treatment with
LT-βR–Ig by 8 weeks.
Mice receiving LT-βR–Ig starting 1 week after inoculation developed
the disease with about 25 days delay as compared to control mice. If
FDC depletion was initiated 1 week before inoculation, the effect on
incubation time was more pronounced. This indicates that FDCs are
essential for deposition of PrPSc and generation of infectivity in the
spleen, and suggest that FDCs participate in the process of neuro-
invasion. Therefore, strategies aimed at depleting FDCs might be
envisaged for post-exposure prophylaxis64 of prion infections initiated at
extracerebral sites65.
Some open questions regarding the lymphotropism of prions
Inhibition of the LT-β signalling pathway with a soluble receptor
depletes FDCs60 and abolishes prion replication in spleen, thereby
prolonging the latency of scrapie after intraperitoneal challenge66. This
suggests that B-cell-deficient µMT mice67 may be resistant to
intraperitoneal prions30 because of impaired FDC maturation32,66.
However, additional experimentation indicates that PrPC-expressing
haematopoietic cells are required in addition to FDCs for efficient
lymphoreticular prion propagation31,35. This apparent discrepancy called
for additional studies of the molecular requirements for prion
replication competence in lymphoid stroma. Therefore, we studied
peripheral prion pathogenesis in mice lacking TNF-α, LT-α/β, or their
receptors.
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After intracerebral inoculation, all treated mice developed clinical
symptoms of scrapie with incubation times, attack rates, and
histopathological characteristics similar to those of wild-type mice,
indicating that TNF/LT signalling is not relevant to cerebral prion
pathogenesis. Upon intraperitoneal prion challenge, mice defective in LT
signalling (LT-α–/–, LT-β–/–, LT-βR–/–, or LT-αTNF-α–/–) proved virtually
non-infectible with ≤ 5 logLD50 scrapie infectivity, and establishment of
subclinical disease68 was prevented. In contrast, TNFR1–/– mice were
almost fully susceptible to all inoculum sizes, and TNF-α-/- mice showed
dose-dependent susceptibility. TNFR2–/– mice had intact FDCs and
germinal centres, and were fully susceptible to scrapie.
Unexpectedly, all examined lymph nodes (Plate XV) of TNFR1–/– and
TNF-α–/– mice had consistently high infectivity titres. Even inguinal
lymph nodes, which are distant from the injection site and do not drain
the peritoneum, contained infectivity titres equal to all other lymph
nodes. Therefore, TNF deficiency prevents lymphoreticular prion
accumulation in spleen but not in lymph nodes.
Why is susceptibility to peripheral prion challenge preserved in the
absence of TNFR1 or TNF-α, while deletion of LT-signalling components
confers high resistance to peripheral prion infection – although each of these
defects (except TNFR2–/–) abolishes FDCs? For one thing, prion
pathogenesis in the lymphoreticular system appears to be compart-
mentalized, with lymph nodes (rather than spleen) being important
reservoirs of prion infectivity during disease. Second, prion replication
appears to take place in lymph nodes even in the absence of mature FDCs.
We generated chimeric mice in order to determine whether haemato-
poietic components are involved in prion propagation in TNFR1–/– lymph
nodes. In Prnpo/o mice grafted with TNFR1–/– haematopoietic cells, high
infectivity loads were detectable in lymph nodes but not spleen, indicating
that TNFR1-deficient haematopoietic cells may support prion propagation
within lymph nodes. These findings are in line with previous studies, which
showed that chimeras of PrP-deficient hosts with PrP-expressing
haematopoietic cells can accumulate prions chronically31,35. The PrP signal
co-localized with a subset of macrophages in TNFR1–/– lymph nodes. Since
marginal zone macrophages are in close contact to FDCs and also interact
with marginal zone B-cells, this cell type is a candidate supporter in prion
uptake and replication.
Sympathetic nerves: a neuro-immune synapse for prions?
A widely discussed model predicts that prion neuro-invasion consists of
two distinct phases – lympho-invasion and neuro-invasion proper69. The
second phase has long been suspected to involve peripheral nerves, and
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may depend on expression of PrPC by nerves70. Studies focusing on the
temporal and spatial dynamics of neuro-invasion have suggested that
the autonomic nervous system might be responsible for transport from
lymphoid organs to the CNS71–74. We have been attempting to test the
requirement for expression of PrPC in peripheral nerves and have
developed a gene transfer protocol to spinal ganglia aimed at resolving
this question75; however, we were never able to recover infectivity in
spinal cords of Prnpo/o mice whose spinal nerves had been transduced by
Prnp-expressing adenoviruses (M Glatzel & A Aguzzi, unpublished
results). Also, fast axonal transport does not appear to be involved in
prion neuro-invasion as mice that are severely impaired in this transport
mechanism experience prion pathogenesis with kinetics similar to that
of wild-type mice76.
There is substantial evidence suggesting that prion transfer from the
lymphoid system to the CNS occurs along peripheral nerves in a PrPC-
dependent fashion31,70,77. The innervation pattern of lymphoid organs is
mainly sympathetic78. Sympathectomy delays the transport of prions
from lymphatic organs to the thoracic spinal cord, which is the entry site
of sympathetic nerves to the CNS. Transgenic mice overexpressing NGF
under control of the K14 promoter, whose spleens are hyperinnervated,
developed scrapie significantly earlier than non-transgenic control mice.
However, many details remain to be elucidated. It is not known whether
prions can be transferred directly from FDCs to sympathetic endings, or
whether additional cell types are involved. The latter possibility is
particularly enticing, as FDCs have not been shown to entertain physical
contact with sympathetic nervous system terminals.
Moreover, it is unclear how prions are actually transported within
peripheral nerves. Axonal and non-axonal transport mechanisms may
be involved. Within the framework of the protein-only hypothesis, one
may hypothesize a ‘domino’ mechanism, by which incoming PrPSc
converts resident PrPC on the axolemmal surface, thereby propagating
spatially the infection. This model may accommodate the finding that
the velocity of neural prion spread is extremely slow79 and may not
follow the canonical mechanisms of fast axonal transport. Recent
studies70,80 may favour a non-axonal transport mechanism that results in
peri-axonal deposition of PrPSc.
The fact that even denervated mice eventually develop scrapie may be
due to: (i) an alternative, low-efficiency route of entry that may become
uncovered by the absence of sympathetic fibres; or (ii) because of
incomplete sympathectomy. Entry through the vagal nerve has been
proposed in studies of the dynamics of vacuolation following oral and
intraperitoneal challenge with prions71,81.
The surprising finding that infectious titres in hyperinnervated spleens
are at least two logs higher and show enhanced PrPSc accumulations
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compared to control mice suggests that sympathetic nerves, besides being
involved in the transport of prions, may also accumulate and replicate
prions in lymphatic organs72. This has implications related to the perman-
ence and possibly eradication of prions in subclinically infected hosts.
Spread of prions within the CNS
Ocular administration of prions has proved particularly useful to study
neural spread of the agent, since the retina is a part of the CNS, and
intra-ocular injection does not produce direct physical trauma to the
brain – which may disrupt the blood-brain barrier and impair other
aspects of brain physiology. The assumption that spread of prions occurs
axonally rests mainly on the demonstration of diachronic spongiform
changes along the retinal pathway following intra-ocular infection8.
To investigate whether spread of prions within the CNS is dependent
on PrPC expression in the visual pathway, PrP-producing neural grafts
were used as sensitive indicators of the presence of prion infectivity in
the brain of an otherwise PrP-less host. Following inoculation with
prions into the eye of grafted Prnpo/o mice, none of the grafts showed
signs of scrapie. Therefore, infectivity administered to the eye of PrP-
deficient hosts cannot induce scrapie in a PrP-expressing neurons
located > 1 synapse away82.
Because engraftment of Prnpo/o mice with PrPC-producing tissue might
lead to an immune response to PrP and possibly to neutralization of
infectivity83. In order to rule out the possibility that prion transport was
disabled by a neutralizing immune response, Prnpo/o mice were rendered
tolerant by expressing PrPC under the control of the lck promoter. These
mice overexpress PrP on T-lymphocytes, but are resistant to scrapie and
do not replicate prions in brain, spleen or thymus after intraperitoneal
inoculation with scrapie prions84. Engraftment of these mice with PrP-
overexpressing neuro-ectoderm did not lead to the development of
antibodies to PrP after intracerebral or intra-ocular inoculation,
presumably due to clonal deletion of PrP-immunoreactive T-
lymphocytes. As before, intra-ocular inoculation with prions did not
provoke scrapie in the graft, supporting the conclusion that lack of PrPC,
rather than immune response to PrP, prevented prion spread82.
Therefore, PrPC appears to be necessary for the spread of prions along
the retinal projections and within the intact CNS.
Therefore, it appears that intracerebral spread of prions is based on a
PrPC-paved chain of cells, perhaps because they are capable of
supporting prion replication. When such a chain is interrupted by
interposed cells that lack PrPC, no propagation of prions to the target
tissue can occur. Perhaps prions require PrPC for propagation across
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synapses: PrPC is present in the synaptic region85 and certain synaptic
properties are altered in Prnpo/o mice86,87. Perhaps transport of prions
within (or on the surface of) neuronal processes is PrPC-dependent.
These findings may be accommodated by a ‘domino-stone’ model10 in
which spreading of scrapie prions in the CNS occurs per continuitatem
through conversion of PrPC by adjacent PrPSc.
Innate immunity and antiprion defence
Cells of the monocyte/macrophage lineage typically represent the first line
of defence against a broad variety of pathogens. In the case of prions, it
might be conceivable that macrophages protect against prions. However, it
would be equally conceivable that macrophages, by virtue of their
phagocytic properties and of their intrinsic mobility, may function as
Trojan horses that transport prion infectivity between sites of replication
within the body. This interesting question has not yet been fully resolved.
In a short-term prion infection paradigm, Beringue and colleagues
administered dichloromethylene disphosphonate encapsulated into
liposomes to mice: this eliminates for a short period of time all spleen
macrophages. Accumulation of newly synthesized PrPSc was accelerated,
suggesting that macrophages participate in the clearance of prions,
rather than being involved in PrPSc synthesis.
Beringue and colleagues suggested that activation or targeting of
macrophages may represent a therapeutic pathway to explore in TSE
infection. This was taken up by Sethi and Kretzschmar, who recently
reported that activation of Toll-like receptors (TLRs), which function as
general stimulators of innate immunity by driving expression of various
sets of the immune regulatory molecules, can effect postexposure
prophylaxis in an experimental model of intraperitoneal scrapie
infection88. Administration of prions intraperitoneally elicited disease
after approximately 180 days, whereas administration of CpG
oligodeoxynucleotides 7 h after prion inoculation and daily for 20 days
led to disease-free intervals of ‘more than 330 days’ – although it
appears that all inoculated mice died of scrapie shortly thereafter
(communicated by H. Kretzschmar at the TSE conference in Edinburgh,
September 2002).
This finding is very surprising, since most available evidence indicates
that general activation of the immune system would typically sensitize mice
to prions, rather than protect them. The mechanism by which activation of
TLR can result in post-exposure prophylaxis is wholly unclear at present,
particularly in view of the fact that mice lacking Myd8889, which is an
essential mediator of TLR signalling, develop prion disease with exactly
the same sensitivity and kinetics as wild-type mice15.
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Another prominent component at the crossroad between innate and
adaptive immunity is represented by the complement system.
Opsonization by complement system components also appears to be
relevant to prion pathogenesis: mice genetically engineered to lack
complement factors36, or mice depleted of the C3 complement
component by administration of cobra venom90, exhibit a remarkable
resistance to peripheral prion inoculation. This phenomenon may, once
again, be related to the pathophysiology of FDCs, which typically
function as antigen traps. Trapping mechanisms essentially consist of
capture of immune complexes by Fcγ receptors, and binding of
opsonized antigens (linked covalently to C3d and C4b complement
adducts) to the CD21/CD35 complement receptors.
Capture mediated by Fcγ receptors does not appear to be important in
prion disease: knockout mice lacking Fcγ receptors91–94 are just as
susceptible to intraperitoneally administered scrapie as wild-type mice.
Further, introduction into µMT mice of a generic immunoglobulin µ-
chain fully restored prion neuro-invasion irrespective of whether this
heavy chain allowed for secretion of immunoglobulins, or only for
production of membrane-bound immunoglobulins. Therefore, we
conclude that circulating immunoglobulins are certainly not crucial to
prion replication in lymphoid organs and to neuro-invasion.
A second mechanism exploited by FDCs for antigen trapping involves
covalent linking of proteolytic fragments of the complement
components C3 and C495,96. Ablation of C3, or of its receptor
CD21/CD35, as well as C1q (alone or combined with BF/C2–/–), delayed
neuro-invasion significantly after intraperitoneal inoculation when a
limiting dose of prions was administered. These effects suggest that
opsonization of the infectious agent may enhance its accessibility to
germinal centres by facilitating docking to FDCs.
Large prion inocula (> 106 infectious units) appear to over-ride the
requirement for a functional complement receptor in prion
pathogenesis. This is similar to systemic viral infections and co-receptor-
dependent retention within the follicular compartment, whose necessity
can be over-ridden by very high affinity antigens97 or adjuvants98.
Additional retention mechanisms for prions may, therefore, exist in
FDCs, which are not complement-dependent, or depend on hitherto
unidentified complement receptors.
Humoral immunity against prions
For many viruses, vaccination is a most effective method of infection
control, but is it possible to induce protective immunity in vivo against
prions? Pre-incubation with anti-PrP antisera was reported to reduce the
Immune system and peripheral nerves in propagation of prions to CNS
British Medical Bulletin 2003;66
154
prion titre of infectious hamster brain homogenates by up to 2 log
units99 and anti-PrP antibodies inhibit formation of PrPSc in a cell-free
system100. Also, antibodies101 and F(ab) fragments raised against certain
domains of PrP102 can suppress prion replication in cultured cells.
However, it is difficult to induce humoral immune responses against
PrPC and PrPSc. This is most likely due to tolerance of the mammalian
immune system to PrPC which is expressed ubiquitously. Ablation of the
Prnp gene103, which encodes PrPC, renders mice highly susceptible to
immunization with prions82, and many monoclonal antibodies to the
prion protein have been generated in Prnpo/o mice104–106. However,
Prnpo/o mice are unsuitable for testing vaccination regimens since they
do not support prion pathogenesis61.
Therefore, we have asked whether genes encoding high-affinity anti-
PrP antibodies (originally generated in Prnpo/o mice) may be utilized to
reprogram B-cell responses of prion-susceptible mice that express PrPC.
Indeed, introduction of the epitope-interacting region the heavy chain of
6H4, a high-affinity anti-PrP monoclonal antibody105 into the germ line
of mice sufficed to produce high-titre anti-PrPC immunity. The build-up
of anti-PrPC titres, however, was slower in the presence of endogenous
PrPC suggesting that some clonal deletion is actually occurring.
How can these observations be interpreted? The total anti-PrPC titre
results from pairing of one transgenic µ-heavy chain with a large repertoire
of endogenous κ- and λ-chains: some pairings may be reactive, while others
may be anergic (Plate XVI). Maybe the B-cell clones with the highest
affinity to PrPC are eliminated by immune tolerization, and only clones
with medium affinity are retained (Plate XVI).
Expression of the 6H4 µ-heavy chain sufficed to confer protection
from scrapie upon intraperitoneal inoculation of the prion agent21. This
delivers proof-of-principle that a protective humoral response against
prions can be mounted by the mammalian immune system, and suggests
that B-cells are not intrinsically tolerant to PrPC. If the latter is generally
true, lack of immunity to prions may be due to T-helper tolerance. To
overcome the latter is not trivial, but there may be ways, some of which
are currently being explored in our laboratory. These findings, therefore,
encourage a re-assessment of the possible value of active and passive
immunization, and perhaps of reprogramming B-cell repertoires by µ-
chain transfer, in prophylaxis or in therapy of prion diseases.
PrP immunization: a tool against prions?
Approximately one year later, a first example of a reduction to practice
of the approach proposed by Heppner was demonstrated in the
laboratory of Wisnieswki. Immunization was simply achieved by
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injecting 50 µg of recombinant prion protein emulsified in Freund’s
adjuvant. This procedure had been utilized extensively in the Zürich
laboratory, but had never produced any reasonable titres in wild-type
mice. Upon inoculation with a high dose or with a lower dose of prion
inoculum, vaccinated mice exhibited a modest delay in development of
prion disease. Although the success of the study, from the viewpoint of
survival of the mice, might be regarded as limited, it does indicate a way
to translate vaccination into models that are closer to the real-life
situation than immunoglobulin-transgenic mice.
Conclusions
Therapy of manifest CJD continues to be unattainable. Therefore, it
might be sensible to concentrate efforts on post-exposure and pre-
exposure prophylaxis. Many promising approaches are being developed
towards these goals: they involve small therapeutic molecules and
cytokine antagonists (post-exposure) as well as specific anti-PrPC
immunity (pre-exposure). Therapy, however, is unlikely to be profitable
for any time to come, since the number of CJD patients is exceedingly
small and will hopefully not increase significantly. It is to be hoped that
national governments and the European Union will agree to consider
this area of funding with some priority, so that the most interesting of
the approaches outlined above will be developed further, and their
usefulness will be proved in clinical settings.
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